Overexpression of the circadian clock gene bmal1 increases sensitivity to oxaliplatin in colorectal cancer

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 1042-1052

  Zeng, Zhao Lei ^a   Luo, Hui Yan ^a,b   Yang, Jing ^a   Wu, Wen Jing ^a   Chen, Dong Liang ^a   Huang, Peng ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN BMAL1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CIRCADIAN RHYTHM; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; MTT ASSAY; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARNTL TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCADIAN CLOCKS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896727511     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0171     Document Type: Article

References (46)

1. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935-41.
2. Panda S, Hogenesch JB, Kay SA. Circadian rhythms from flies to human. Nature 2002;417:329-35.
3. Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging 2011;3:479-93.
4. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 2010;330:1349-54.
5. Ikeda M, Nomura M. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage. Biochem Biophys Res Commun 1997;233:258-64.
6. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
7. Duong HA, Robles MS, Knutti D, Weitz CJ. A molecular mechanism for circadian clock negative feedback. Science 2011;332:1436-9.
8. Khapre RV, Kondratova AA, Susova O, Kondratov RV. Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle 2011;10:4162-9.
9. Shimba S, Ishii N, Ohta Y, Ohno T, Watabe Y, Hayashi M, et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci U S A 2005;102: 12071-6.
10. Sun Y, Yang Z, Niu Z, Peng J, Li Q, Xiong W, et al. MOP3, a component of the molecular clock, regulates the development of B cells. Immunology 2006;119:451-60.
11. Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 2009;69:8447-54.
12. Lee J, KimMS, Li R, Liu VY, Fu L, Moore DD, et al. Loss of Bmal1 leads to uncoupling and impaired glucose-stimulated insulin secretion in beta-cells. Islets 2011;3:381-8.
13. Geyfman M, Kumar V, Liu Q, Ruiz R, Gordon W, Espitia F, et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci U S A 2012;109:11758-63.
14. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS ONE 2009;4:e4798.
15. Grechez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem 2008;283:4535-42.
16. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375:1030-47.
17. Pollack LA, Gotway CA, Bates JH, Parikh-Patel A, Richards TB, Seeff LC, et al. Use of the spatial scan statistic to identify geographic variations in late stage colorectal cancer in California (United States). Cancer Causes Control 2006;17:449-57.
18. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44.
19. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
20. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6.
21. Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007;59:1015-35.
22. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010;50: 377-421.
23. Filipski E, Delaunay F, King VM,WuMW,Claustrat B, Grechez-Cassiau A, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res 2004;64:7879-85.
24. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 2009;69:4700-7.
25. Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 2012;131:2684-92.
26. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002;22:2111-23.
27. Zeng ZL, Wu WJ, Yang J, Tang ZJ, Chen DL, Qiu MZ, et al. Prognostic relevance of melanomaantigen D1expression in colorectal carcinoma. J Transl Med 2012;10:181.
28. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and downregulating Akt activity in breast cancer cells. Cancer Res 2007;67: 5083-9.
29. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009;15:1393-9.
30. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005;19:2153-8.
31. Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, et al. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res 2012;18:4059-69.
32. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A 2005;102:3407-12.
33. Zeng ZL,WuMW, Sun J, Sun YL, Cai YC, Huang YJ, et al. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem 2010;148:319-26.
34. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007;47:593-628.
35. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350-61.
36. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-9.
37. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007;26:7741-8.
38. Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, van der Horst GT. Phase resetting of the mammalian circadian clock by DNA damage. Curr Biol 2008;18:286-91.
39. Yang X, Wood PA, Hrushesky WJ. Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem 2010;285:3030-4.
40. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms 2007;22:291-8.
41. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375-82.
42. Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov 2004;3:11-2.
43. Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999-1005.
44. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int 2011;28:841-51.
45. Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep 2011;25:1439-46.
46. Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, et al. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int J Cancer 2012;131:2820-31.